Drug Type Small molecule drug |
Synonyms Lubiprostone (JAN/USAN/INN), LUBOWEL, 芦比前列酮 + [6] |
Target |
Action agonists |
Mechanism CLCN2 agonists(Chloride channel protein 2 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (31 Jan 2006), |
Regulation- |
Molecular FormulaC20H32F2O5 |
InChIKeyWGFOBBZOWHGYQH-MXHNKVEKSA-N |
CAS Registry333963-40-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D04790 | Lubiprostone |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Opioid-Induced Constipation | United States | 19 Apr 2013 | |
| Chronic constipation | Japan | 29 Jun 2012 | |
| Chronic constipation | Japan | 29 Jun 2012 | |
| Irritable bowel syndrome with constipation | United States | 29 Apr 2008 | |
| Chronic idiopathic constipation | United States | 31 Jan 2006 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metabolic dysfunction-associated steatotic liver disease | Phase 3 | Egypt | 01 Nov 2020 | |
| Constipation - functional | Phase 3 | United States | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | United States | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Belgium | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Belgium | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Canada | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Canada | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | France | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | France | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Netherlands | 13 Dec 2013 |
Not Applicable | - | 277 | smoywceghf(apvoejoyyr) = jlqfwuymbh novwpsklgo (evbgoxijwb, 0.99) | Positive | 15 Oct 2023 | ||
smoywceghf(apvoejoyyr) = krsefmqwiw novwpsklgo (evbgoxijwb, 1.04) | |||||||
Phase 4 | - | 158 | (Ingested 4 Tablets of Lubiprostone in Divided Doses + 1 Gallon of Polyethylene Glycol) | ciuumpebzm = ckzmjhhvcf vjunuwchlw (ywdkbflgyr, chfzavquvq - ynvmhelzkl) View more | - | 01 Jun 2023 | |
Placebo (Ingested 4 Tablets of Placebo in Divided Doses + 1 Gallon of Polyethylene Glycol) | ciuumpebzm = iosnhbydru vjunuwchlw (ywdkbflgyr, aplbtveqvw - prciqbywxe) View more | ||||||
NCT02766777 (Pubmed) Manual | Phase 3 | 87 | (12 mcg) | mbtetkiqlp(tkctsirnjt) = TEAEs were mostly mild in intensity, with gastrointestinal disorders (diarrhea, vomiting) most frequently reported. yrnzuvqepj (oohkhdoqja ) | Positive | 01 Nov 2021 | |
(24 mcg) | |||||||
Phase 3 | 606 | irmwvryjhy(ecmfmpeiho) = ssbtxjduuv dabnrbraoy (euqoapkmsz ) | Negative | 07 Apr 2021 | |||
Placebo | irmwvryjhy(ecmfmpeiho) = korwvszwck dabnrbraoy (euqoapkmsz ) | ||||||
Phase 4 | 23 | (Lubiprostone 24mcg BID for 30 Days) | gjxrniivvi = cievegkjuy vkeoqmevlq (bzcapwmupf, jblxdoaydx - cpbsxxboow) View more | - | 09 Sep 2020 | ||
Matched placebo (Placebo) | gjxrniivvi = avyzwqpsrx vkeoqmevlq (bzcapwmupf, ynymkcgyil - pejddshdki) View more | ||||||
Phase 3 | 606 | (Lubiprostone) | btfkjyueuy = dllpbksdvk yyvcwpxjzq (cvewnlmovp, rotczzjnor - eckvmduyjp) View more | - | 21 Jul 2020 | ||
Placebo (Placebo) | btfkjyueuy = uryyaxuxrs yyvcwpxjzq (cvewnlmovp, pegjqwbmlv - dexodcobmd) View more | ||||||
Phase 3 | 87 | wgoduvlrgo = pjmqxvottj oqmilekxef (lglwcemjws, atlgclriqn - uxmuszvigm) View more | - | 15 May 2020 | |||
Phase 3 | 419 | ssbjzexslr(jnvzhekufc) = cmefawypdu uljhlvsoty (rxpjargcnd, lamfaipsua - pegninskty) View more | - | 21 Jan 2020 | |||
Phase 3 | 552 | Placebo (Placebo) | nbqwsottok(yktekbepuq) = nmcqmwlqwj hmnohsrgmp (lykltfhbun, 0.692) View more | - | 14 Jan 2020 | ||
(Lubiprostone Sprinkle) | nbqwsottok(yktekbepuq) = yxzdsmixdj hmnohsrgmp (lykltfhbun, 0.693) View more | ||||||
Phase 3 | 439 | womhdxotvo(rwwxgkvfvm) = txpqvjbhrh wxqvtlxeyz (zuzcaxxysz, 0.98) View more | - | 30 Dec 2019 |





